Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 23264901)

1.
2.

Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.

Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG.

Cancer Immunol Immunother. 2007 Jun;56(6):885-95. Epub 2006 Nov 11.

PMID:
17102977
3.

Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.

Johnson LE, McNeel DG.

Prostate. 2012 May 15;72(7):730-40. doi: 10.1002/pros.21477. Epub 2011 Aug 30.

PMID:
22529020
4.

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.

Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG.

J Immunother. 2010 Jul-Aug;33(6):639-47. doi: 10.1097/CJI.0b013e3181dda23e.

5.

Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).

Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG.

Vaccine. 2006 Jan 16;24(3):293-303. Epub 2005 Aug 9.

PMID:
16115700
6.

Identification of T helper epitopes from prostatic acid phosphatase.

McNeel DG, Nguyen LD, Disis ML.

Cancer Res. 2001 Jul 1;61(13):5161-7.

7.

Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.

Dobaño C, Doolan DL.

Mol Immunol. 2007 Apr;44(11):3037-48. Epub 2007 Feb 15.

PMID:
17303242
8.

DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques.

Chikhlikar P, Barros de Arruda L, Maciel M, Silvera P, Lewis MG, August JT, Marques ET.

PLoS One. 2006 Dec 27;1:e135.

10.
11.

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.

Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG.

J Immunol. 2001 Dec 15;167(12):7150-6.

12.

Priming biologically active antibody responses against an isolated, conformational viral epitope by DNA vaccination.

Riedl P, El-Kholy S, Reimann J, Schirmbeck R.

J Immunol. 2002 Aug 1;169(3):1251-60.

13.

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.

Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY.

Clin Cancer Res. 2003 Aug 15;9(9):3260-71.

14.

Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope.

Kianizad K, Marshall LA, Grinshtein N, Bernard D, Margl R, Cheng S, Beermann F, Wan Y, Bramson J.

Cancer Res. 2007 Jul 1;67(13):6459-67.

15.
17.

Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.

Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB.

Prostate. 2007 Jul 1;67(10):1019-28.

PMID:
17455230
18.

Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.

Kaumaya PT, Kobs-Conrad S, Seo YH, Lee H, VanBuskirk AM, Feng N, Sheridan JF, Stevens V.

J Mol Recognit. 1993 Jun;6(2):81-94.

PMID:
7508238
19.

A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.

Lundberg K, Roos AK, Pavlenko M, Leder C, Wehrum D, Guevara-Patiño J, Andersen RS, Pisa P.

Vaccine. 2009 Mar 4;27(10):1557-65. doi: 10.1016/j.vaccine.2009.01.011. Epub 2009 Jan 24.

PMID:
19171173
20.

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G.

J Clin Oncol. 2009 Sep 1;27(25):4047-54. doi: 10.1200/JCO.2008.19.9968. Epub 2009 Jul 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk